Goldline Pharmaceutical appoints secretarial auditor for FY26

Goldline Pharmaceutical Ltd has appointed M/s. Avinash Gandhewar & Associates as its Secretarial Auditor for the financial year 2025-26. The Board of Directors approved the appointment during a meeting held on July 14, 2026. The firm will conduct the secretarial audit for the period from April 1, 2025, to March 31, 2026.

The appointment is in compliance with Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The disclosure follows the requirements outlined in SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

M/s. Avinash Gandhewar & Associates is a peer-reviewed firm with expertise in Company Law, Securities Laws, Legal Due Diligence, Joint Ventures, FEMA, Public Offering (SME IPO), Mergers and Acquisitions, and NCLT matters. The firm is based in Nagpur and will serve as the Secretarial Auditor for the specified financial year.

Details of Appointment

Particulars	Disclosure
Name	M/s Avinash Gandhewar & Associates
Reason for Change	Appointed as a Secretarial Auditor of the Company for the financial year 2025-2026
Date of appointment	Appointed in the board meeting held on July 14, 2026 to conduct the Secretarial Audit for the financial year 2025-26
Terms of appointment	To conduct Secretarial Audit for the financial year 2025-26

The firm's registered office is located at Jagat Housing Society, Sundaram Apartments, Flat No. C-104, Near Wonderland School, Opp. ICAD, Byramji Town, Chahoni, Nagpur-440013.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.64%	+3.56%	-8.02%	-31.30%	-31.30%	-31.30%

Goldline Pharmaceutical Limited disclosed that its promoter and Whole Time Director, Swapan Khandelwal, has increased his stake in the company by acquiring 60,000 equity shares. The transaction, executed through the open market on June 22, 2026, represents 0.62% of the total issued and paid-up share capital. This acquisition signals increased promoter confidence in the pharmaceutical entity.

The disclosure was submitted to BSE Limited on June 23, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing detailed the change in shareholding pattern resulting from the open market purchase. Ruchi Sanket Modi, the Company Secretary cum Compliance Officer, authenticated the submission on behalf of the company.

Prior to the acquisition, Khandelwal held 2,749,988 equity shares, which accounted for 28.65% of the company's total voting capital. Following the purchase of 60,000 shares, his total holding has risen to 2,809,988 equity shares. This new stake translates to 29.27% of the total share capital, solidifying his position as a key shareholder in the firm.

The total equity share capital of Goldline Pharmaceutical Limited remains unchanged at 9,600,000 equity shares. There were no changes in the encumbrance status or holdings in warrants and convertible securities. The entire transaction was settled via the open market route without any preferential allotment or inter-se transfer mechanisms.